To validate the clinical relevance of our findings, FoxM1 activation in KRASm/WT+ was also confirmed in surgical biospecimens collected from NSCLC patients affected by lung adenocarcinoma. This evidence concerns the gene FOXM1 and lung adenocarcinoma.